Benzinga··Vandana SinghFDA Expands Dupixent Approval to Allergic Fungal Rhinosinusitis
FDA approves Dupixent for allergic fungal rhinosinusitis in patients six and older, marking the drug's ninth indication for treating type 2 inflammatory conditions.
SNYREGNFDA approvalPhase 3 trial